| Country | Type | Number | Dated | Case |
| United States Of America | Published Application | 20250283112 | 09/11/2025 | 2022-112 |
RNA editing offers an exciting opportunity to modify genetic information without permanently altering the underlying DNA. While conventional RNA splicing occurs naturally within a single RNA molecule (in cis), existing technologies have been limited in their ability to precisely modify RNA using separate RNA molecules.
Researchers at UC Berkeley have developed an innovative hybrid RNA technology that enables targeted RNA modification through trans-splicing, joining two distinct RNA molecules. The platform combines a programmable targeting region with a donor RNA to direct the modification of specific target transcripts.
By enabling RNA modification without permanent genomic changes, this technology offers several compelling advantages, including potentially reversible genetic modulation, greater flexibility in therapeutic design, and opportunities to correct or replace disease-associated RNA sequences. Its programmable architecture also creates opportunities for applications in genetic medicine, functional genomics, and the development of next-generation RNA therapeutics.
By bringing programmable editing to the RNA level, this technology opens a new frontier in genetic medicine, offering a potentially flexible and reversible alternative to permanent DNA editing.